$AUPH

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991_q22026earningsr.htm EX-99.1 Document Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress ROCKVILLE, Maryland and EDMONTON, Alberta – August 6, 2026 – A

The article says investors are rotating from highly valued AI infrastructure toward healthcare, citing a Bank of America survey and recent sector performance. It highlights three healthcare stocks: Aurinia Pharmaceuticals (AUPH) with Q1 revenue $77.7M and EPS $0.25; Fortrea (FTRE) raising full-year sales and adjusted EBITDA; and Aveanna (AVAH) after a $175.5M acquisition, guiding FY revenue $2.63B-$2.65B.

Aurinia Pharmaceuticals (NASDAQ: AUPH) opened Monday trading flat after launching PRESERVE, a Phase 4 multicenter study of LUPKYNIS® plus belimumab, obinutuzumab, or anifrolumab in lupus nephritis. About 150 patients across ~50 US sites will be enrolled. Primary endpoint is complete renal response at six months.

Aurinia Pharmaceuticals (NASDAQ:AUPH) said it has started the Phase 4 PRESERVE study in lupus nephritis to test LUPKYNIS with belimumab, obinutuzumab, or anifrolumab. Enrollment targets ~150 patients across ~50 US sites. The primary endpoint is complete renal response at 6 months.

Moneylife’s weekly market breadth stayed in bullish territory. The news list includes FDA inspection outcomes for Lupin and Ajanta Pharma (both VAI), Bank of Baroda paying US$600mn to settle NMC Health litigation, and multiple corporate updates: NTPC’s final 41.6MW solar segment at Ramagundam, V2 Retail Q1FY26-27 revenue ₹997 crore (+58%), and Adani Ports Q1FY26-27 cargo +15% y/y to 138.1 MMT.

Aurinia Pharmaceuticals CEO Kevin Tang bought 814,606 shares in multiple transactions from May 29 to June 2, 2026, totaling about $12.5 million, according to an SEC Form 4. The weighted average purchase price was $15.29. Tang holds no direct shares but has indirect holdings of 13,044,106 shares plus exposure via short put options. Aurinia shares closed at $15.29 on June 2.

Aurinia Pharmaceuticals CEO Kevin Tang bought 814,606 common shares for about $12.5 million in multiple transactions from May 29 to June 2, 2026, according to an SEC Form 4. The shares were acquired indirectly via affiliated investment funds; Tang reported no direct holdings before or after. The weighted average purchase price was $15.29, near the June 2 close.

Indian markets were set to open flat-to-mildly positive, with Gift Nifty around 23,550. Zee Entertainment was up to Rs 109.49; Sterlite Technologies to Rs 677.90. HDFC Mutual Fund temporarily restricted lump-sum subscriptions in its Gold ETF. Aurobindo Pharma said USFDA granted final approval for Tofacitinib tablets. Focus was on RBI policy and FII outflows.

TANG KEVIN (Chief Executive Officer) purchased 206,005 indirectly-held shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.28 ($3.15M total) on 2026-06-02.